<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533091</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP151</org_study_id>
    <nct_id>NCT00533091</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis</brief_title>
  <official_title>A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of multiple IV&#xD;
      doses of MEDI-545 in adult patients with myositis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of multiple&#xD;
      intravenous (IV) doses of MEDI-545 in adult patients with dermatomyositis (DM) or&#xD;
      polymyositis (PM).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoints of the study are safety and tolerability of multiple intravenous (IV) doses of MEDI-545 in adult patients with Dermatomyositis or Polymyositis, assessed primarily by summarizing AEs assessing changes in viral cultures and titers.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints of the study are the PK and IM of multiple IV doses of MEDI-545.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The third endpoint of the study are the evaluations of disease activities.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>DERMATOMYOSITIS OR POLYMYOSITIS</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MEDI-545</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-545</intervention_name>
    <description>MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.&#xD;
Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.&#xD;
Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.&#xD;
Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adults at least 18 years of age at the time of randomization;&#xD;
&#xD;
          -  Written informed consent obtained from the patient or the patient's legal&#xD;
             representative prior to receipt of any study medication or beginning study procedures;&#xD;
&#xD;
          -  Probable or definite PM or DM according to the Bohan and Peter criteria (Bohan, 1975);&#xD;
&#xD;
          -  For patients with PM, documentation of a muscle biopsy result that is consistent with&#xD;
             the diagnosis of PM;&#xD;
&#xD;
          -  All patients including those with DM must meet at least two of the following criteria:&#xD;
&#xD;
          -  Strength in MMT greater ≥ 80/150 but ≤ 125/150 using the MMT-8 muscle group testing;&#xD;
&#xD;
          -  Patient Global Activity Assessment by visual analog scale (VAS)≥ 2.0 cm on a 10 cm&#xD;
             scale, which is included as part of CLINHAQ;&#xD;
&#xD;
          -  Physician Global Activity Assessment by VAS ≥ 2.0 cm on a 10 cm scale, which is&#xD;
             included as part of MDAAT;&#xD;
&#xD;
          -  CLINHAQ disability index ≥ 0.25;&#xD;
&#xD;
          -  Global extramuscular activity assessment ≥ 1.0 cm on a 10-cm VAS scale (this measure&#xD;
             is the physician's composite evaluation and is based on assessments of activity scores&#xD;
             on the constitutional, cutaneous, skeletal, gastrointestinal, pulmonary and&#xD;
             cardiovascular scales of the MDAAT;&#xD;
&#xD;
          -  Subjects with PM must have an elevation of serum CK or aldolase at a minimum level of&#xD;
             1.3 x upper limit of normal (ULN) or serum CK or aldolase at least 2-fold higher than&#xD;
             the patient's own lowest value since diagnosis;&#xD;
&#xD;
          -  Subjects with DM must have either an elevated CK or aldolase as above (per inclusion&#xD;
             criterion #6) or other laboratory evidence of active myositis. This could include&#xD;
             either abnormal signal on skeletal muscle MRI suggestive of inflammation or an&#xD;
             electromyogram demonstrated muscle membrane irritability (e.g., fibrillation&#xD;
             potentials, positive sharp waves, complex repetitive discharges) and short duration,&#xD;
             small amplitude, polyphasic motor unit action potentials;&#xD;
&#xD;
          -  For patients randomized to Dose Cohorts 1.2, 3A and 4: median fold overexpression of&#xD;
             the top 25 type I IFN inducible genes of four-fold or greater in whole blood at the&#xD;
             time of screening; For patients randomized to dose cohort 3B: low or negative&#xD;
             expression of type I IFN-inducible genes;&#xD;
&#xD;
          -  Sexually active women, unless surgically sterile (including tubal ligation) or at&#xD;
             least 2 years postmenopausal, must use an effective method of avoiding pregnancy&#xD;
             (including oral, injectable, transdermal, or implanted contraceptives, intrauterine&#xD;
             device, diaphragm with spermicide, cervical cap, abstinence, and sterile sexual&#xD;
             partner) in addition to the use of condoms (male or female condoms with spermicide)&#xD;
             from screening through end of study. Cessation of birth control after this point&#xD;
             should be discussed with a responsible physician. Sexually active males, unless&#xD;
             surgically sterile, must likewise practice two effective methods of birth control&#xD;
             (condom with spermicide or abstinence) and must use such precautions from Study Day 0&#xD;
             through end of study;&#xD;
&#xD;
          -  Ability to complete the study period, including follow-up period, of up to 350 days;&#xD;
             and&#xD;
&#xD;
          -  Willing to forego other forms of experimental treatment during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of MEDI-545 in any previous clinical study or prior randomization into the&#xD;
             trial;&#xD;
&#xD;
          -  History of allergy or reaction to any component of the study drug formulation;&#xD;
&#xD;
          -  Inclusion body myositis, cancer-associated myositis, myositis associated with another&#xD;
             connective tissue disease, environmentally-associated myositis, or drug-related&#xD;
             myopathy;&#xD;
&#xD;
          -  A history of or a family history of noninflammatory myopathy, scapular winging,&#xD;
             atrophy, or hypertrophy of the calf muscles;&#xD;
&#xD;
          -  Receiving prednisone &gt; 35 mg/day (or an equivalent dose of another corticosteroid)&#xD;
             within 14 days before Study Day 0;&#xD;
&#xD;
          -  Receiving the following dosages of medications within 28 days before Study Day 0:&#xD;
             hydroxychloroquine &gt; 600 mg/day, mycophenolate mofetil &gt; 3 g/day, methotrexate &gt; 25&#xD;
             mg/week, azathioprine &gt; 3 mg/kg/day, or any dose of cyclophosphamide, cyclosporine, or&#xD;
             thalidomide;&#xD;
&#xD;
          -  Have received fluctuating doses of antimalarials, mycophenolate mofetil, methotrexate,&#xD;
             leflunomide, or azathioprine within 28 days before Study Day 0 or fluctuating doses of&#xD;
             corticosteroids within 14 days before Study Day 0;&#xD;
&#xD;
          -  Have received leflunomide &gt; 20 mg/day in the 6 months prior to Study Day 0;&#xD;
&#xD;
          -  Treatment with any investigational drug therapy within 28 days before Study Day 0 or&#xD;
             biologic therapies (eg, rituximab) within 30 days or 5 half-lives of the biologic&#xD;
             agent, whichever is longer, before Study Day 0;&#xD;
&#xD;
          -  In the investigator's opinion, evidence of clinically significant active infection,&#xD;
             including ongoing, chronic infection, within 28 days before Study Day 0;&#xD;
&#xD;
          -  A history of severe viral infection as judged by the investigators, including severe&#xD;
             infections of either CMV or the herpes family such as disseminated herpes, herpes&#xD;
             encephalitis, ophthalmic herpes;&#xD;
&#xD;
          -  Herpes zoster ≤ 3 months prior to Study Day 0;&#xD;
&#xD;
          -  Evidence of infection with hepatitis B or C virus or HIV-1 or HIV-2, or active&#xD;
             infection with hepatitis A, as determined by results of testing at screening;&#xD;
&#xD;
          -  Vaccination with live attenuated viruses within 28 days before Study Day 0;&#xD;
&#xD;
          -  Pregnancy (sexually active women, unless surgically sterile or at least 2 years&#xD;
             post-menopausal, must have a negative serum pregnancy test at screening and a negative&#xD;
             urine pregnancy test prior to study drug administration on Study Day 0);&#xD;
&#xD;
          -  Breastfeeding or lactating women;&#xD;
&#xD;
          -  History of alcohol or drug abuse &lt; 1 year prior to Study Day 0;&#xD;
&#xD;
          -  History of cancer, except for basal cell carcinoma or carcinoma in situ of the cervix&#xD;
             treated with apparent success with curative therapy more than 1 year prior to Study&#xD;
             Day 0;&#xD;
&#xD;
          -  History of active tuberculous infection;&#xD;
&#xD;
          -  History of latent tuberculous infection or newly positive TB skin test (reaction&#xD;
             defined as ≥ 10 mm in diameter if not on systemic immunosuppressive medication or ≥ 5&#xD;
             mm if on systemic immunosuppressive medication) without completion of an appropriate&#xD;
             course of treatment or ongoing prophylactic therapy;&#xD;
&#xD;
          -  A history of coagulation disorders that in the opinion of the investigator would&#xD;
             contraindicate skin or muscle biopsies;&#xD;
&#xD;
          -  Elective surgery planned from the time of screening through Study Day 196;&#xD;
&#xD;
          -  At screening blood tests (must be within 28days before Study Day 0) any of the&#xD;
             following:&#xD;
&#xD;
               -  Serum creatinine &gt; 4.0 mg/dL,&#xD;
&#xD;
               -  Neutrophils &lt; 1,500/mm3,&#xD;
&#xD;
               -  Platelet count &lt; 50,000/mm3;&#xD;
&#xD;
          -  History of any disease, evidence of any current disease (other than DM or PM), any&#xD;
             finding upon physical examination, or any laboratory abnormality, that, in the opinion&#xD;
             of the investigator or medical monitor, may compromise the safety of the patient in&#xD;
             the study or confound the analysis of the study; or&#xD;
&#xD;
          -  Any employee of the research site who is involved with the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Ethgen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>May 25, 2012</last_update_submitted>
  <last_update_submitted_qc>May 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
    <mesh_term>Polymyositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sifalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

